Improve Research Reproducibility A Bio-protocol resource
- Home
- Protocols
-
Ask a
question
Favorite
The decision to treat patients with 20% SCIG was based on the judgment of patients' treating physician in accordance with normal clinical practice.
During the prospective phase of the study, all patients received biweekly (every 14 ± 2 days) Hizentra 20% SCIG. Patients or caregivers received training on drug administration from their nurses or treating physician in the hospital. SCIG therapy was administered at home using pumps for subcutaneous drug infusion (Crono S-PID, Canè S.r.l., Italy).
Copyright and License information: ©2019, Mary Ann Liebert, Inc., publishers
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Post a Question0 Q&A
